A Neuroendocrine Tumor of Unknown Primary Origin that Responded to Treatment Based on Tumor Grade Progression
-
- Hamano Yukako
- Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Japan
-
- Moriwaki Toshikazu
- Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Japan
-
- To Keii
- Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Japan
-
- Watahiki Takahisa
- Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Japan
-
- Yamada Takeshi
- Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Japan
-
- Sakashita Shingo
- Department of Pathology, Faculty of Medicine, University of Tsukuba, Japan
-
- Hyodo Ichinosuke
- Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Japan
この論文をさがす
説明
<p>The standard chemotherapies for neuroendocrine tumors (NETs) are somatostatin analog (SSA) and targeted-agents for NET G1/G2 and platinum-based chemotherapy for neuroendocrine carcinoma (NEC), classified according to the WHO criteria of 2010. We report a case of NET, in which tumors were successfully treated with platinum-containing chemotherapy after remarkable progression with SSA. A 46-year-old man with multiple lymph nodes and liver metastases of unknown primary origin was diagnosed with NET G2 based on the examination of a biopsy specimen. His tumors were stable with SSA for a year, but rapidly became enlarged. A second biopsy revealed NEC. He received cisplatin plus etoposide, and his tumors showed a marked reduction in size. </p>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 58 (8), 1087-1091, 2019-04-15
一般社団法人 日本内科学会